Microbiome Therapeutics
Biotechnology ResearchColorado, United States11-50 Employees
Microbiome Therapeutics is a Biotechnology company located in 11001 W 120th Ave, Broomfield, Colorado, United States.
Strategic Partnerships Microbiome Therapeutics has experience in forming strategic partnerships with companies like PetGiftz, presenting an opportunity for collaborative marketing agreements and expanding product reach.
Innovative Product Launches The successful launch of BiomeBliss, a patented prebiotic dietary supplement, showcases Microbiome Therapeutics' ability to innovate and introduces potential opportunities for new product developments in the digestive health sector.
Funding and Financial Stability With a recent Series B financing of $1 million, Microbiome Therapeutics demonstrates financial stability, indicating potential for investment opportunities or collaborations with interested investors.
Market Expansion The launch of the microbiome modulator by Microbiome Therapeutics shows an intent for market expansion, indicating room for growth opportunities in penetrating new market segments or geographic areas.
Competitive Advantage In comparison to similar companies like MyMD Pharmaceuticals and Intra-Cellular Therapies, Microbiome Therapeutics could leverage its unique product offerings in the biotechnology sector to gain a competitive advantage and increase market share.
Microbiome Therapeutics uses 7 technology products and services including Google Analytics, WordPress, Google Font API, and more. Explore Microbiome Therapeutics's tech stack below.
Microbiome Therapeutics Email Formats | Percentage |
Biotechnology ResearchColorado, United States11-50 Employees
Microbiome Therapeutics is a Biotechnology company located in 11001 W 120th Ave, Broomfield, Colorado, United States.
Microbiome Therapeutics has raised a total of $1M of funding over 1 rounds. Their latest funding round was raised on Nov 01, 2017 in the amount of $1Mas a Series B.
Microbiome Therapeutics has raised a total of $1M of funding over 1 rounds. Their latest funding round was raised on Nov 01, 2017 in the amount of $1Mas a Series B.